FDA approves Watson's generic version of Boniva

PARSIPPANY, N.J. — The Food and Drug Administration has approved Watson's generic version of a drug used to prevent and treat osteoporosis in post-menopausal women, the company said.

Watson announced the FDA's approval of ibandronate tablets in the 150-mg strength, a generic version of Genentech's Boniva. Watson plans to launch its version in second quarter 2012.

On Monday, the FDA approved generic ibandronate tablets in the same strength made by Mylan, Apotex and Orchid Healthcare. Boniva had sales of $510 million during the 12-month period ended in January, according to IMS Health.

Watson said Roche, Genentech's parent company, had filed suit against it with regard to the drug, alleging patent infringement.

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.